|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Purdue_Pharma_L.P.
|
|
gptkbp:advertising
|
aggressive marketing strategies
controversial marketing campaigns
|
|
gptkbp:affiliation
|
various medical associations
|
|
gptkbp:CEO
|
gptkb:Mark_Timney
|
|
gptkbp:claims
|
multiple states
|
|
gptkbp:clinicalTrials
|
conducted for pain medications
|
|
gptkbp:communityOutreach
|
opioid education programs
|
|
gptkbp:controversy
|
marketing practices
|
|
gptkbp:corporateSocialResponsibility
|
initiatives to combat addiction
|
|
gptkbp:court
|
gptkb:U.S._Bankruptcy_Court
|
|
gptkbp:dissolved
|
2021
|
|
gptkbp:drugInterdiction
|
contributed to epidemic
|
|
gptkbp:employees
|
approximately 1,000
|
|
gptkbp:financialPerformance
|
declined post-2019
|
|
gptkbp:financials
|
various health initiatives
|
|
gptkbp:founded
|
1996
|
|
gptkbp:founder
|
gptkb:John_Purdue_Gray
|
|
gptkbp:headquarters
|
gptkb:Stamford,_Connecticut
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Purdue Pharma Inc.
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:investmentFocus
|
research and development
managed through bankruptcy process
|
|
gptkbp:keyPeople
|
gptkb:Richard_Sackler
|
|
gptkbp:legal_principle
|
billions paid in settlements
|
|
gptkbp:legalStatus
|
opioid crisis
|
|
gptkbp:market
|
OxyContin (1996)
after bankruptcy settlement.
|
|
gptkbp:marketShare
|
significant in opioid market
|
|
gptkbp:notableEvent
|
gptkb:OxyContin
|
|
gptkbp:notableFeature
|
$8 billion (2020)
|
|
gptkbp:parentCompany
|
gptkb:Purdue_Pharma_L.P.
|
|
gptkbp:partnerships
|
various healthcare organizations
with healthcare providers
|
|
gptkbp:philanthropy
|
gptkb:Purdue_Pharma_Foundation
|
|
gptkbp:productLine
|
none reported
|
|
gptkbp:products
|
opioid analgesics
focused on pain relief
new formulations of opioids
nationwide_in_the_U.S.
|
|
gptkbp:publicAccess
|
regarding opioid crisis
|
|
gptkbp:publicPerception
|
negative due to opioid crisis
|
|
gptkbp:reform
|
post-bankruptcy plan
|
|
gptkbp:regulatoryCompliance
|
FDA_scrutiny
|
|
gptkbp:researchFocus
|
pain management
|
|
gptkbp:researchInterest
|
awarded for pain research
|
|
gptkbp:revenue
|
$3 billion (2018)
|
|
gptkbp:scholarships
|
September 2019
|
|
gptkbp:subsidiary
|
gptkb:Purdue_Pharma_L.P.
|
|
gptkbp:website
|
www.purduepharma.com
|